Cost analysis for health economic modelling
Cost analysis to support development or adaptations of the health economic models in 19 European countries
This website uses cookies to ensure you get the best experience on our website. By carrying on browsing, you are giving your consent for us to set cookies.

Learn more
Ok, I agree
Close
Cost analysis is an essential part of any economic analysis for medical technologies of medicinal products.

Cost data are obtained from two sources: from the published literature and the reimbursement documentation.

MTRC offers the highest quality of cost analysis to support the development of the models or adaptation of the models, based on the extensive experience with coding and reimbursement in the hospital and ambulatory sector of 19 European countries.

Also, MTRC can perform the complete adaptation of the model to the settings of other European countries.

How it works
1
Scoping
Exact understanding of the objective and the audience of the model is required as well as the details of the procedure and the perspective of the analysis
2
Literature search
Systematic literature search is performed in Medline, Medline In-Process and NHS Economic Evaluation Database. All decisions for selection of articles are documented. Preference is given to the cost studies using the right perspective (hospital, health care system, societal)
3
Micro-costing and obtaining tariffs
When cost data are not available, a micro-costing approach is used. In some cases, reimbursement tariffs are obtained using the official reimbursement sources and MTRC Good Clinical Coding Practice
4
Literature search for epidemiological and quality of life data (optional)
If required, MTRC can perform a complete model adaptation, including the literature search for epidemiological and quality of life data, run the analysis
5
Writing the report
MTRC prepares the report in the required format

Key benefits
Pan-European support
Analysis in 19 EU countries by the same vendor. Save money and time
Specialized clinical coding provider
MTRC has one of the largest clinical coding groups in European consulting industry
Well-document decisions and report
Details of literature search, selection criteria, coding scenarios are documented to support publications and HTA submissions

Our services cover 19 European countries including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland and Turkey

Our publications
Our team has in-depth understanding of the requirements for cost analysis to support publications in peer-reviewed journals, HTA and reimbursement submissions in Europe
Veličković VM, Borisenko O, Svensson M, Spelman T, Siebert U. Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. PLoS One. 2018 Sep 27;13(9):e0204643.
O Borisenko, J Müller-Ehmsen, JA Lindenfeld, E Rafflenbeul, C Hamm. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovascular Disorders, 2018. 18:163.
Borisenko O, Lukyanov V, Ahmed A.R. Cost-utility analysis of bariatric surgery. Br J Surg. 2018 Apr 17. doi: 10.1002/bjs.10857.
Borisenko O, Lukyanov V, Debergh I, Dillemans B. Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. J Med Econ. 2018 Jan 10:1-9.
Sanchez-Santos R, Padin EM, Adam D, Borisenko O, Fernandez SE, Dacosta EC, Fernández SG, Vazquez JT, de Adana JCR, de la Cruz Vigo F. Bariatric surgery versus conservative management for morbidly obese patients in Spain: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2017 Nov 30:1-10.
Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V, Simon-Talero M, Cordoba J, Angeli P, Rosi S, MacDonald S, Malago M, Stepanova M, Younossi ZM, Trepte C, Watson R, Borisenko O, Sun S, Inhaber N, Jalan R. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenterrandomized controlled study. J Hepatol. 2017 Nov;67(5):940-949.
Sun S, Borisenko O, Spelman T, Ahmed AR. Patient Characteristics, Procedural and Safety Outcomes of Bariatric Surgery in England: a Retrospective Cohort Study-2006-2012. Obes Surg. 2017 Oct 26. doi: 10.1007/s11695-017-2978-x.
Borisenko O, Mann O, Duprée A. Cost-utility analysis of bariatric surgery compared with conventional medical management in Germany: a decision analytic modeling. BMC Surg. 2017 Aug 3;17(1):87.
O Borisenko, V Lukyanov, SP Johnsen, P Funch-Jensen. Cost analysis of bariatric surgery in Denmark made with a decision-analytic model. Dan Med J 2017;64(8):A5401
Lucchese M, Borisenko O, Mantovani LG, Cortesi PA, Cesana G, Adam D, Burdukova E, Lukyanov V, Di Lorenzo N. Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. Obes Facts. 2017 Jun 10;10(3):261-272.
Zhang R, Borisenko O, Telegina I, Hargreaves J, Ahmed AR, Sanchez Santos R, Pring C, Funch-Jensen P, Dillemans B, Hedenbro JL. Systematic review of risk prediction models for diabetes after bariatric surgery. Br J Surg, 2016 Oct;103(11);1420-7.
Miikkulainen K, Caruso A, Mast O, Zhang R, Borisenko O. Systematic literature review of use of blood glucose monitoring in phase III clinical studies of insulin analogs. BMC Endocr Disord. 2016 May 4;16(1):21.
Borisenko O, Haude M, Hoppe UC, Siminiak T, Lipiecki J, Goldberg SL, Mehta N, Bouknight OV, Bjessmo S, Reuter DG. Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings. BMC Cardiovasc Disord. 2015 May. 14;15(1):43.
Borisenko O, Adam D, Funch-Jensen P, Ahmed R Ahmed, Zhang R, Colpan Z, Hedenbro J. Bariatric surgery can lead to net cost savings to health care systems: results from a comprehensive European decision analytic model. Obes Surg. 2015 Sep;25(9):1559-68.
Borisenko O, Colpan Z, Dillemans B, Funch-Jensen P, Hedenbro J, Ahmed R Ahmed. Clinical Indications, Utilization and Funding of Bariatric Surgery in Europe. Obes Surg. 2015 Aug;25(8):1408-16.
Borisenko O, Wylie G, Payne J, Bjessmo S, Smith J, Yonan N, Firmin R. Thoratec CentriMag for temporary treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency: a systematic literature review and meta-analysis of observational studies. ASAIO J. 2014 Sep-Oct;60(5):487-97.
Borisenko O, Wylie G, Payne J, Bjessmo S, Smith J, Firmin R, Yonan N. The cost impact of short-term ventricular assist devices and extracorporeal life support systems therapies on the National Health Service in the UK. Interact Cardiovasc Thorac Surg. 2014 Jul;19(1):41-8.
Borisenko O, Beige J, Lovett EG, Hoppe UC, Bjessmo S. Cost-Effectiveness of Barostim Therapy for the Treatment of Resistant Hypertension in European Settings. J Hypertens. 2014 Mar;32(3):681-92.
Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW Jr, Mäkelä M. Antibiotics for acute maxillary sinusitis in adults. Cochrane Database Syst Rev. 2014 Feb 11;2:CD000243.
Roos JB, Doshi SN, Konorza T, Palacios I, Schreiber T, Borisenko OV, Henriques JP. The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective. J Med Econ. 2013;16(3):381-90.

MTRC has unique insights into economic evidence requirements of European reimbursement and HTA organizations

About MTRC
A specialized hospital and Med Tech consultancy
13 out of top-30 global Med Tech companies routinely use reimbursement services of MTRC

Coverage of 19 European markets

>120 reimbursement projects per year

15 full-time employees, located in six European countries

Main web-sites: Med Tech, Pharma, Online school in market access
Contact us
Contact us to learn more about our capabilities to address your needs